Cadrenal (NASDAQ: CVKD) touts $2B revenue as FDA agrees on Phase 3 design
Rhea-AI Filing Summary
Cadrenal Therapeutics, Inc. (CVKD) reported that the FDA provided positive feedback in a Type D Meeting held on July 28, 2026, aligning with the company on key elements of the protocol and Statistical Analysis Plan for a Phase 3 registrational study of CAD-1005 in heparin-induced thrombocytopenia (HIT).
The FDA agreed to an optimized definition of worsening HIT for the composite primary endpoint, focusing on progression of thrombotic events or hospital discharge through Day 14, including extension of existing thrombi into new vascular segments. The agency also agreed to a placebo-controlled design, with both CAD-1005 and placebo arms receiving standard anticoagulation, and to assess bleeding using International Society on Thrombosis and Haemostasis criteria. Cadrenal highlights HIT as a ~50,000 patient acute market in the U.S. and cites a projected $2 billion peak annual revenue opportunity for CAD-1005.
Positive
- FDA alignment on the Phase 3 registrational design for CAD-1005 in HIT, including primary endpoint, placebo control, and safety assessments, clarifies the regulatory path for this late-stage program.
- CAD-1005 targets an estimated 50,000 acute HIT cases annually in the U.S., and the company cites a projected $2 billion peak annual revenue opportunity, highlighting the perceived commercial potential.
Negative
- None.
Filing Explained
The company reports that the planned Phase 3 study will also treat bleeding as a major safety endpoint under ISTH criteria, with safety analyses covering participants who receive at least one dose; this updates the evaluation plan but does not indicate that the trial has been completed.
8-K Event Classification
3 items: 7.01, 8.01, 9.01
3 items
Item 7.01
Regulation FD Disclosure
Disclosure
Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.
Item 8.01
Other Events
Other
Voluntary disclosure of events the company deems important to shareholders but not covered by other items.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Key Figures
Acute HIT cases annually in U.S.: 50,000 patients
Projected peak annual revenue for CAD-1005: $2 billion
Primary endpoint assessment period: Day 14
+2 more
5 metrics
Acute HIT cases annually in U.S.
50,000 patients
Estimated number of confirmed acute HIT diagnoses in the U.S. each year
Projected peak annual revenue for CAD-1005
$2 billion
Company-cited peak annual revenue opportunity for CAD-1005 in HIT
Primary endpoint assessment period
Day 14
Composite thromboembolic events measured through Day 14 of treatment or hospital discharge
FDA Type D Meeting date
July 28, 2026
Date FDA and Cadrenal aligned on key Phase 3 CAD-1005 design elements
Press release date
August 31, 2026
Date Cadrenal announced FDA Type D Meeting outcome
Key Terms
Type D Meeting, Serotonin Release Assay-positive (SRA+), thromboembolic events, International Society on Thrombosis and Haemostasis (ISTH), +2 more
6 terms
Type D Meeting regulatory
"positive feedback from a Type D Meeting with the U.S. Food and Drug"
Serotonin Release Assay-positive (SRA+) medical
"measure the proportion of Serotonin Release Assay-positive (SRA+) participants"
A serotonin release assay-positive (SRA+) result means a laboratory functional test found that a patient’s antibodies cause platelets to release serotonin when exposed to heparin, which is the hallmark laboratory evidence of heparin‑induced thrombocytopenia (HIT). It matters to investors because an SRA+ finding signals a verified, potentially serious drug‑safety issue or adverse event that can affect clinical trial outcomes, regulatory review, product labeling, liability, and market confidence—similar to a stress test showing a critical fault under normal operating conditions.
thromboembolic events medical
"new or worsening composite thromboembolic events through Day 14 or"
Thromboembolic events are serious medical incidents where a blood clot forms and travels through the bloodstream to block a vessel, like a clot causing a stroke or a lung embolism; think of it as a sudden pipe blockage inside the body. For investors, these events matter because they can signal safety risks for drugs or devices, trigger regulatory action, costly recalls or lawsuits, and materially affect a company’s sales, valuation and future approvals.
International Society on Thrombosis and Haemostasis (ISTH) medical
"bleeding as a major safety endpoint using standard International Society"
Orphan Drug Designation regulatory
"CAD-1005 has an Orphan Drug Designation (“ODD”) from the U.S."
Orphan drug designation is a special status given to medicines developed to treat rare diseases affecting only a small number of people. This status often provides benefits like faster approval processes and financial incentives, making it more attractive for companies to develop these drugs. For investors, it signals potential for exclusive market rights and reduced competition, which can impact the drug’s profitability.
Fast Track designation regulatory
"CAD-1005, FDA Fast Track designation for the treatment and prevention"
Fast track designation is a status the U.S. Food and Drug Administration grants to drugs intended to treat serious conditions and address an unmet medical need. It gives the developer more frequent communication with the FDA and can allow parts of the application to be reviewed on a rolling basis, and it may pave the way to priority review or accelerated approval. It can shorten development timelines, though it does not guarantee approval.
FAQ
What did Cadrenal Therapeutics (CVKD) announce about its FDA Type D Meeting?
Cadrenal Therapeutics announced positive feedback from an FDA Type D Meeting, where the FDA and the company aligned on protocol and Statistical Analysis Plan details for a Phase 3 registrational trial of CAD-1005 in heparin-induced thrombocytopenia (HIT), including the primary efficacy and safety endpoints.
How will the primary endpoint be defined in Cadrenal Therapeutics (CVKD) Phase 3 CAD-1005 trial?
The primary endpoint will be a composite measuring the proportion of Serotonin Release Assay-positive participants with adjudicated new or worsening thromboembolic events through Day 14 or hospital discharge, including extension of an existing thrombus into a new vascular segment or bed.
What control arm did the FDA agree to for CVKD’s Phase 3 CAD-1005 study?
The FDA agreed that the Phase 3 CAD-1005 study can use a placebo control, with both the CAD-1005 and placebo arms receiving existing standard anticoagulation therapies, supporting a blinded, controlled design for evaluating efficacy and safety in HIT.
What market opportunity does Cadrenal Therapeutics (CVKD) see for CAD-1005 in HIT?
Cadrenal states that approximately 50,000 patients in the U.S. are diagnosed with acute HIT each year and cites a projected $2 billion peak annual revenue opportunity for CAD-1005 as an add-on therapy to standard anticoagulation.
How will safety be evaluated in the Phase 3 CAD-1005 trial for CVKD?
The Phase 3 CAD-1005 trial will assess bleeding as a major safety endpoint using standard International Society on Thrombosis and Haemostasis (ISTH) criteria, with safety analyses conducted in patients who receive at least one dose of the study drug.
What other pipeline programs did Cadrenal Therapeutics (CVKD) highlight?
Cadrenal highlighted CAD-1005 for HIT and CSA-AKI, second-generation 12-LOX oral therapeutics (CAD-2000) for chronic indications, and tecarfarin, a late-stage oral vitamin K antagonist that has received Orphan Drug and Fast Track designations from the FDA.
AI-generated analysis. How Rhea-AI works. Not financial advice.
